|
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) |
|
Amphastar Pharmaceuticals Inc
AMPH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Amphastar Pharmaceuticals Inc growth rates, revenue grew
by 4.32 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 645
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Amphastar Pharmaceuticals Inc 's net profit decreased by -45.77 % in IV. Quarter 2024 year on year, to $27 millions.
• More on AMPH's Growth
|
|
Amphastar Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Amphastar Pharmaceuticals Inc PEG ratio is at 0.73
Amphastar Pharmaceuticals Inc realized cash reduction of $ -2.29 per share in trailing twelve-month period. |
Company |
8.36 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on AMPH's Valuation
|
|
|
|
|
Amphastar Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Amphastar Pharmaceuticals Inc PEG ratio is at 0.73
Amphastar Pharmaceuticals Inc realized cash outflow of $ -2.29per share in trailing twelve-month period. |
Company |
8.36 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
Amphastar Pharmaceuticals Inc Price to Book Ratio is at 1.67 lower than Industry Avg. of 77.28. and higher than S&P 500 Avg. of 0.01
• More on AMPH's Valuation
|
|
AMPH's Profitability Comparisons
|
Amphastar Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 14.7 % from 29.83 % in III. Quarter.
Amphastar Pharmaceuticals Inc net profit margin of 14.17 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 95 in Healthcare sector and number 1090 in S&P 500.
Profitability by Segment |
Total |
21.14 % |
|
|
Amphastar Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 14.7 % from 29.83 % in III. Quarter.
Amphastar Pharmaceuticals Inc net profit margin of 14.17 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 95 in Healthcare sector and number 1090 in S&P 500.
• More on AMPH's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com